Профилактика, алгоритм ведения, анестезия и интенсивная терапия при послеродовых кровотечениях. Клинические рекомендации
#2019-3
PDF_2019-3_9-33
HTML_2019-3_9-33

Ключевые слова

акушерство
атония матки
геморрагический шок
гемостатическая терапия
ДВС-синдром
инфузионно-трансфузионная терапия
коагулопатия
нарушения свертывающей системы крови
послеродовое кровотечение
травма родовых путей
утеротонические препараты

Как цитировать

Шифман Е.М., Куликов А.В., Роненсон А.М., Абазова И.С., Адамян Л.В., Андреева М.Д., Артымук Н.В., Баев О.Р., Баринов С.В., Белокриницкая Т.Е., Блауман С.И., Братищев И.В., Бухтин А.А., Вартанов В.Я., Волков А.Б., Гороховский В.С., Долгушина Н.В., Дробинская А.Н., Кинжалова С.В., Китиашвили И.З., Коган И.Ю., Королев А.Ю., Краснопольский В.И., Кукарская И.И., Курцер М.А., Маршалов Д.В., Матковский А.А., Овезов А.М., Пенжоян Г.А., Пестрикова Т.Ю., Петрухин В.А., Приходько А.М., Протопопова Н.В., Проценко Д.Н., Пырегов А.В., Распопин Ю.С., Рогачевский О.В., Рязанова О.В., Савельева Г.М., Семенов Ю.А., Ситкин С.И., Фаткуллин И.Ф., Федорова Т.А., Филиппов О.С., Швечкова М.В., Шмаков Р.Г., Щеголев А.В., Заболотских И.Б. Профилактика, алгоритм ведения, анестезия и интенсивная терапия при послеродовых кровотечениях. Клинические рекомендации. Вестник интенсивной терапии имени А.И. Салтанова. 2019;(3):9–33. doi:10.21320/1818-474X-2019-3-9-33.

Статистика

Просмотров аннотации: 376
PDF_2019-3_9-33 загрузок: 57
HTML_2019-3_9-33 загрузок: 666
Статистика с 21.01.2023

Аннотация

В статье отражены основные положения клинических рекомендаций по профилактике, анестезии и интенсивной терапии при послеродовых кровотечениях. Последовательно представлены основные факторы риска, возможные осложнения, принципы клинической и лабораторной диагностики при данной патологии. Особое внимание уделено вопросам инфузионной, трансфузионной терапии и коррекции коагулопатических нарушений. Обсуждены проблемы оценки величины кровопотери, диагностики нарушений системы гемостаза, регуляции гемодинамики при геморрагическом шоке. Обосновано применение рекомбинантных факторов свертывания крови при коагулопатии на фоне массивной кровопотери.
https://doi.org/10.21320/1818-474X-2019-3-9-33
PDF_2019-3_9-33
HTML_2019-3_9-33

Библиографические ссылки

  1. Lier H., Schlembach D., Korte W., et al. [The new German guideline on postpartum haemorrhage (PPH): essential aspects for coagulation and circulatory therapy]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2016; 51(9): 526–535. DOI:10.1055/s-0042-105937
  2. Mavrides E., Allard S., Chandraharan E., et al. On behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and Management of Postpartum Haemorrhage. BJOG An Int J Obstet Gynaecol. 2017; 124(5): e106–149. DOI:10.1111/1471–0528.14178
  3. Takeda S., Makino S., Takeda J., et al. Japanese Clinical Practice Guide for Critical Obstetrical Hemorrhage (2017 revision). J Obstet Gynaecol Res. 2017; 43(10): 1517–1521. DOI:10.1111/jog.13417
  4. Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017; 130(4): e168–186. DOI:10.1097/AOG.0000000000002351
  5. Le Bas A., Chandraharan E., Addei A., Arulkumaran S. Use of the “obstetric shock index” as an adjunctinid entify in signify cant blood loss in patients with massive postpartum hemorrhage. Int J Gynaecol Obstet. 2014; 124(3): 253–255.
  6. Shields L.E., Wiesner S., Fulton J., Pelletreau B. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. Am J Obstet Gynecol. 2015; 212(3): 272–80. DOI:10.1016/j.ajog.2014.07.012
  7. Russell R.T. WHO guidelines for the management of postpartum haemorrhage and retained placenta. Hum Fertil. 2011; 14(2): 129–129. DOI:10.3109/14647273.2010.529650
  8. Carroli G., Cuesta C., Abalos E., Gulmezoglu A.M. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008; 22(6): 999–1012. DOI:10.1016/j.bpobgyn.2008.08.004
  9. Say L., Chou D., Gemmill A., et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Heal. 2014; 2(6): e323–e333. DOI:10.1016/S2214–109X(14)70227-X
  10. Creanga A.A., Berg C.J., Ko J.Y., et al. Maternal mortality and morbidity in the United States: where are we now? J Womens Health (Larchmt). 2014; 23(1): 3–9. DOI:10.1089/jwh.2013.4617
  11. Mallett S.A.M. Point-of-care monitoring of haemostasis. Anaesthesia. 2015; 70(1): 73–77.
  12. Fowler A.P.D. Laboratory monitoring of haemostasis. Anaesthesia. 2015; 70(1): 68–72.
  13. Brooks M., Legendre G., Brun S., et al. Use of a Visual Aid in addition to a Collector Bag to Evaluate Postpartum Blood loss: A Prospective Simulation Study. Sci Rep. 2017; 7:46333. DOI:10.1038/srep46333
  14. Lilley G., Burkett-St.-Laurent D., Precious E., et al. Measurement of blood loss during postpartum haemorrhage. Int J Obstet Anesth. 2015; 24(1): 8–14. DOI:10.1016/j.ijoa.2014.07.009
  15. Diaz V., Abalos E.C.G. Methods for blood loss estimation after vaginal birth. Cochrane Database Syst Rev. 2018; Sep13(9).
  16. Patel A., Goudar S.S., Geller S.E., et al. Drape estimation vs. visual assessment for estimating postpartum hemorrhage. Int J Gynaecol Obstet. 2006; 93(3): 220–224. DOI:10.1016/j.ijgo.2006.02.014
  17. Glover P. Blood loss at delivery: how accurate is your estimation? Aust J Midwifery. 2003; 16(2): 21–24.
  18. Al Kadri H.M.F., Al Anazi B.K., Tamim H.M. Visual estimation versus gravimetric measurement of postpartum blood loss: a prospective cohort study. Arch Gynecol Obstet. 2011; 283(6): 1207–1213. DOI:10.1007/s00404-010-1522-1
  19. Zuckerwise L.C., Pettker C.M., Illuzzi J., Raab C.R., Lipkind H.S. Use of a novel visual aid to improve estimation of obstetric blood loss. Obstet Gynecol. 2014; 123(5): 982–986. DOI:10.1097/AOG.0000000000000233
  20. Girault A., Deneux-Tharaux C., Sentilhes L., et al. Undiagnosed abnormal postpartum blood loss: Incidence and risk factors. PLoS One. 2018; 13(1): e0190845. DOI:10.1371/journal.pone.0190845
  21. American College of Surgeons Committee on Trauma. ATLS® Student Manual 9th Edition. Chicago, IL: American College of Surgeons. 2012.
  22. Knight M., Nair M., Tuffnell D., et al. Surveillance of maternal deaths in the UK 2012–14 and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009–14. 2016.
  23. Green M., Rider C., Ratcliff D., Woodring B.C. Developing a Systematic Approach to Obstetric Emergencies. J Obstet Gynecol neonatal Nurs JOGNN. 44(5): 677–682. DOI:10.1111/1552–6909.12729
  24. Bajaj K., Rivera-Chiauzzi E.Y., Lee C., et al. Validating Obstetric Emergency Checklists using Simulation: A Randomized Controlled Trial. Am J Perinatol. 2016; 33(12): 1182–1190. DOI:10.1055/s-0036-1586118
  25. Guise J.-M., Mladenovic J. In situ simulation: identification of systems issues. Semin Perinatol. 2013; 37(3): 161–165. DOI:10.1053/j.semperi.2013.02.007
  26. Guise J.-M., Lowe N.K., Deering S., et al. Mobile in situ obstetric emergency simulation and teamwork training to improve maternal-fetal safety in hospitals. Jt Comm J Qual patient Saf. 2010; 36(10): 443–453.
  27. Obstetric Care Consensus No. 5: Severe Maternal Morbidity: Screening and Review. Obstet Gynecol. 2016; 128(3): e54–60. DOI:10.1097/AOG.0000000000001642
  28. American College of Obstetricians and Gynecologists Committee on Patient Safety and Quality Improvement. Committee opinion no. 590: preparing for clinical emergencies in obstetrics and gynecology. Obstet Gynecol. 2014; 123(3): 722–725. DOI:10.1097/01.AOG.0000444442.04111.c6
  29. Likis F., Sathe N., Morgans A., et al. Management of Postpartum Hemorrhage. Comparative Effectiveness Review No. 151. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2012-00009-I.) AHRQ Publication No. 15-EHC013-EF. Rockville, MD: Agency for Healthcare Researc.
  30. Рекомендации ВОЗ по профилактике и лечению послеродового кровотечения, 2012. http://apps.who.int/iris/bitstream/handle/10665/75411/ 9789244548509_rus.pdf. [WHO recommendation for prevention and treatment postpartum hemorrhage, 2012. http://apps.who.int/iris/bitstream/handle/10665/75411/ 9789244548509_rus.pdf. (In Russ)]
  31. Gutierrez M.C., Goodnough L.T., Druzin M., Butwick A.J. Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: a retrospective study. Int J Obstet Anesth. 2012; 21(3): 230–235. DOI:10.1016/j.ijoa.2012.03.005
  32. Ahonen J., Jokela R., Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand. 2007; 51(7): 929–936. DOI:10.1111/j.1399-6576.2007.01323.x
  33. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017; 389(10084): 2105–2116. DOI:10.1016/S0140–6736(17)30638-4
  34. Schlembach D., Helmer H., Henrich W., et al. Peripartum Haemorrhage, Diagnosis and Therapy. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). Geburtshilfe Frauenheilkd. 2018; 78(4): 382–399. DOI:10.1055/a-0582-0122
  35. Burtelow M., Riley E., Druzin M., et al. How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol. Transfusion. 2007; 47(9): 1564–1572. DOI:10.1111/j.1537-2995.2007.01404.x
  36. Grottke O., Levy J.H. Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology. 2015; 122(4): 923–931. DOI:10.1097/ALN.0000000000000608
  37. Dzik W.H., Blajchman M.A., Fergusson D., et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products — Massive transfusion consensus conference 2011: report of the panel. Crit Care. 2011; 15(6): 242. DOI:10.1186/cc10498
  38. Mavrides E., Allard S., Chaandraharan E., et al. On behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage. BJORG. 2016; 124.
  39. Berg C.J., Harper M.A., Atkinson S.M., et al. Preventability of pregnancy-related deaths: results of a state-wide review. Obstet Gynecol. 2005; 106(6): 1228–1234. DOI:10.1097/01.AOG.0000187894.71913.e8
  40. Clark S.L., Belfort M.A., Dildy G.A., et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008; 199(1): 36.e1–5; discussion 91–2, e7–11. DOI:10.1016/j.ajog.2008.03.007
  41. Callaghan W.M., Kuklina E.V., Berg C.J. Trends in postpartum hemorrhage: United States, 1994–2006. Am J Obstet Gynecol. 2010; 202(4): 353.e1–6. DOI:10.1016/j.ajog.2010.01.011
  42. Callaghan W.M., Mackay A.P., Berg C.J. Identification of severe maternal morbidity during delivery hospitalizations, United States, 1991–2003. Am J Obstet Gynecol. 2008; 199(2): 133.e1–8. DOI:10.1016/j.ajog.2007.12.020
  43. Kavle J.A., Stoltzfus R.J., Witter F., et al. Association between anaemia during pregnancy and blood loss at and after delivery among women with vaginal births in Pemba Island, Zanzibar, Tanzania. J Health Popul Nutr. 2008; 26(2): 232–240.
  44. Soltani H., Hutchon D.R., Poulose T.A. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane database Syst Rev. 2010;(8): CD006173. DOI:10.1002/14651858.CD006173.pub2
  45. Oladapo O.T., Okusanya B.O., Abalos E. Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour. Cochrane database Syst Rev. 2018; 9: CD009332. DOI:10.1002/14651858.CD009332.pub3
  46. Mousa H.A., Blum J., Abou El Senoun G., et al. Treatment for primary postpartum haemorrhage. Cochrane database Syst Rev. 2014;(2): CD003249. DOI:10.1002/14651858.CD003249.pub3
  47. Westhoff G., Cotter A.M., Tolosa J.E. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane database Syst Rev. 2013;(10): CD001808. DOI:10.1002/14651858.CD001808.pub2
  48. Novikova N., Hofmeyr G.J., Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane database Syst Rev. 2015;(6): CD007872. DOI:10.1002/14651858.CD007872.pub3
  49. Franchini M., Mengoli C., Cruciani M., et al. Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis. Blood Transfus. 2018; 16(4): 329–337. DOI:10.2450/2018.0026–18
  50. Shakur H., Beaumont D., Pavord S., et al. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane database Syst Rev. 2018; 2: CD012964. DOI:10.1002/14651858.CD012964
  51. WHO Guidelines Approved by the Guidelines Review Committee. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Geneva: World Health Organization; 2018.
  52. Jin B., Du Y., Zhang F., et al. Carbetocin for the prevention of postpartum hemorrhage: a systematic review and meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med. 2016; 29(3): 400–407. DOI:10.3109/14767058.2014.1002394
  53. Su L.-L., Chong Y.-S., Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane database Syst Rev. 2012;(4): CD005457. DOI:10.1002/14651858.CD005457.pub4
  54. Anandakrishnan S., Balki M., Farine D., et al. Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2. Can J Anaesth. 2013; 60(11): 1054–1060. DOI:10.1007/s12630-013-0028-2
  55. Dyer R.A., van Dyk D., Dresner A. The use of uterotonic drugs during caesarean section. Int J Obstet Anesth. 2010; 19(3): 313–319. DOI:10.1016/j.ijoa.2010.04.011
  56. WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. World Heal Organ. 2018.
  57. Leung S.W., Ng P.S., Wong W.Y., Cheung T.H. A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour. BJOG. 2006; 113(12): 1459–1464. DOI:10.1111/j.1471-0528.2006.01105.x
  58. Шифман Е.М., Куликов А.В. и др. Анестезия и интенсивная терапия при массивной кровопотере в акушерстве. Клинические рекомендации (протоколы лечения). Вопросы гинекологии, акушерства и перинатологии. 2018; 17(3): 81–100. DOI: 10.20953/1726-1678-2018-3-81-100 [Shifman E.M., Kulikov A.V., et al. Anesthesia and intensive care in massive obstetric haemorrhage. Clinical guidelines (Treatment protocol) Gynecology, Obstetrics and Perinatology. 2018; 17 (3): 81–100. (In Russ)]
  59. Cannon J.W. Hemorrhagic Shock. N Engl J Med. 2018; 378(4): 370–379. DOI:10.1056/NEJMra1705649
  60. Cecconi M., De Backer D., Antonelli M., et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014; 40(12): 1795–815. DOI:10.1007/s00134-014-3525-z
  61. Taylor F.B., Toh C.H., Hoots W.K., et al. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5): 1327–1330.
  62. Squizzato A., Hunt B.J., Kinasewitz G.T., et al. Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost. 2016; 115(5): 896–904. DOI:10.1160/TH15-09-0740
  63. Erez O. Disseminated intravascular coagulation in pregnancy — Clinical phenotypes and diagnostic scores. Thromb Res. 2017; 151 Suppl: S56–S60. DOI:10.1016/S0049–3848(17)30069–5
  64. Clark S.L., Romero R., Dildy G.A., et al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 2016; 215(4): 408–412. DOI:10.1016/j.ajog.2016.06.037
  65. Lyndon A., Lagrew D., Shields L., et al. Improving health care response to obstetric hemorrhage version 2.0. A California quality improvement toolkit. Stamford (CA): California Maternal Quality Care Collaborative; Sacramento (CA): California Department of Public Health. 2015.
  66. Wikkelsø A., Wetterslev J., Møller A.M., Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017; 72(4): 519–531. DOI:10.1111/anae.13765
  67. Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane database Syst Rev. 2016;(8): CD007871. DOI:10.1002/14651858.CD007871.pub3
  68. Fahrendorff M., Oliveri R.S., Johansson P.I. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products — A systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2017; 25(1): 39. DOI:10.1186/s13049-017-0378-9
  69. Whiting P., Al M., Westwood M., et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015; 19(58): 1–228, v–vi. DOI:10.3310/hta19580
  70. Llau J.V., Acosta F.J., Escolar G., et al. Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document). Med intensiva. 2015; 39(8): 483–504. DOI:10.1016/j.medin.2015.05.002
  71. Queensland clinical guidelines. Primary postpartum haemorrage.
  72. Kozek-Langenecker S.A. Fluids and coagulation. Curr Opin Crit Care. 2015; 21(4): 285–91. DOI:10.1097/MCC.0000000000000219
  73. Sommer N., Schnüriger B., Candinas D., Haltmeier T. Massive transfusion protocols in nontrauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2019; 86(3): 493–504. DOI:10.1097/TA.0000000000002101
  74. Tanaka H., Matsunaga S., Yamashita T., et al. A systematic review of massive transfusion protocol in obstetrics. Taiwan J Obstet Gynecol. 2017; 56(6): 715–718. DOI:10.1016/j.tjog.2017.10.001
  75. Bhangu A., Nepogodiev D., Doughty H., Bowley D.M. Meta-analysis of plasma to red blood cell ratios and mortality in massive blood transfusions for trauma. Injury. 2013; 44(12): 1693–1699. DOI:10.1016/j.injury.2012.07.193
  76. Snegovskikh D., Souza D., Walton Z. et al. Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage. J Clin Anesth. 2018; 44: 50–56. DOI:10.1016/j.jclinane.2017.10.003
  77. Butwick A.J., Goodnough L.T. Transfusion and coagulation management in major obstetric hemorrhage. Curr Opin Anaesthesiol. 2015; 28(3): 275–284. DOI:10.1097/ACO.0000000000000180
  78. Collis R.E., Collins P.W. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015; 70 Suppl 1:78–86, e27–8. DOI:10.1111/anae.12913
  79. Postpartum Haemorrhage, Prevention and Management (Green-top Guideline No. 52). December 2016.
  80. Reddy S., Weinberg L., Young P. Crystalloid fluid therapy. Crit Care. 2016; 20(20): 59. DOI:10.1186/s13054-016-1217-5
  81. National Clinical Guideline Centre (UK). Intravenous Fluid Therapy: Intravenous Fluid Therapy in Adults in Hospital. R Coll Physicians. 2013.
  82. Kozek-Langenecker S.A., Afshari A., Albaladejo P., et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30(6): 270–382. DOI:10.1097/EJA.0b013e32835f4d5b
  83. Rossaint R., Bouillon B., Cerny V., et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016; 20(1): 100. DOI:10.1186/s13054-016-1265-x
  84. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology. 2015; 122(2): 241–275.
  85. Blood Transfusion in Obstetrics Royal College of Obstetricians and Gynaecologists/. RCOG Green-top Guidel No 47. 2015.
  86. Hovaguimian F., Myles P.S. Restrictive versus Liberal Transfusion Strategy in the Perioperative and Acute Care Settings: A Context-specific Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesiology. 2016; 125(1): 46–61. DOI:10.1097/ALN.0000000000001162
  87. Goucher H., Wong C.A., Patel S.K., Toledo P. Cell Salvage in Obstetrics. Anesth Analg. 2015; 121(2): 465–468. DOI:10.1213/ANE.0000000000000786
  88. Доброхотова Ю.Э., Джобава Э.М., Данелян С.Ж., Залесская С.А. Послеродовые кровотечения. Обоснование оптимальной гемостатической фармакотерапии. Российский вестник акушера-гинеколога. 2013;(6): 99–102. [Dobrokhotova Yu.E., Dzhobava E.M., Danelyan S.Zh., Zalesskaya S.A. Postpartum hemorrhage. Postpartum hemorrhage. Rationale for optimal hemostatic pharmacotherapy. Russian Bulletin of Obstetrician-Gynecologist. 2013; (6): 99–102. (In Russ)]
  89. Bolliger D., Mauermann E., Tanaka K.A. Thresholds for Perioperative Administration of Hemostatic Blood Components and Coagulation Factor Concentrates: An Unmet Medical Need. J Cardiothorac Vasc Anesth. 2015; 29(3): 768–776. DOI:10.1053/j.jvca.2015.02.023
  90. Alfirevic Z., Elbourne D., Pavord S., et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000–2004. Obstet Gynecol. 2007; 110(6): 1270–1278. DOI:10.1097/01.AOG.0000288515.48066.99
  91. Huber A.W., Raio L., Alberio L., et al. Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study. J Perinat Med. 2011; 40(1): 43–49. DOI:10.1515/JPM.2011.109
  92. Phillips L.E., McLintock C., Pollock W et al., Australian and New Zealand Haemostasis Registry. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg. 2009; 109(6): 1908–1915. DOI:10.1213/ANE.0b013e3181c039e6
  93. Lavigne-Lissalde G., Aya A.G., Mercier F.J., et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015; 13(4): 520–529. DOI:10.1111/jth.12844
  94. Franchini M., Manzato F., Salvagno G.L., Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007; 18(7): 589–593. DOI:10.1097/MBC.0b013e32822d2a3c
  95. Brenner B., Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology. 2007; 12(1): 55–62. DOI:10.1080/10245330601111573
  96. Shah N.M., Chong S.E., Yusoff S.M., et al. A. Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience. BMC Hematol. 2018; 18:34. DOI:10.1186/s12878-018-0126-z
  97. Liumbruno G.M., Liumbruno C., Rafanelli D. Intraoperative cell salvage in obstetrics: is it a real therapeutic option? Transfusion. 2011; 51(10): 2244–2256. DOI:10.1111/j.1537-2995.2011.03116.x
  98. Tevet A., Grisaru-Granovsky S., Samueloff A., Ioscovich A. Peripartum use of cell salvage: a university practice audit and literature review. Arch Gynecol Obstet. 2012; 285(2): 281–284. DOI:10.1007/s00404-011-2164-7
  99. Greenawalt J.A., Zernell D. Autologous Blood Transfusion for Postpartum Hemorrhage. MCN Am J Matern Child Nurs. 42(5): 269–275. DOI:10.1097/NMC.0000000000000359
  100. Lim G., Melnyk V., Facco F.L., et al. Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. Anesthesiology. 2018; 128(2): 328–337. DOI:10.1097/ALN.0000000000001981
  101. Кровесберегающие технологии в акушерской практике. Клинические рекомендации (протокол лечения). Письмо Министерства здравоохранения Российской Федерации от 27 мая 2014 г. № 15-4/10/2-379839. [Blood saving technologies in obstetric practice. Clinical recommendations (treatment protocol). The letter of the Ministry of Health of the Russian Federation of May 27, 2014 N 15-4/10/2-379839. (In Russ)]
  102. Waters J.H., Biscotti C., Potter P.S., Phillipson E. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000; 92(6): 1531–1536.
  103. Working Party, Association of Anaesthetists of Great Britain & Ireland, Obstetric Anaesthetists’ Association, Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists’ Association Regional Anaesthesia UK. Anaesthesia. 2013; 68(9): 966–972. DOI:10.1111/anae.12359
  104. Horlocker T.T., Vandermeuelen E., Kopp S.L., et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018; 43(3): 263–309. DOI:10.1097/AAP.0000000000000763
  105. El Khouly N.I. Comparison of intravenous ferrous sucrose and oral ferrous sulphate in treatment of postpartum iron deficiency anemia. J Matern Fetal Neonatal Med. 2017; 30(8): 967–971. DOI:10.1080/14767058.2016.1192602
Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-ShareAlike» («Атрибуция — Некоммерческое использование — На тех же условиях») 4.0 Всемирная.